Heparin-mediated extracorporeal low-density lipoprotein precipitation: Rationale for a specific adjuvant therapy in cardiovascular disease

Transfusion and Apheresis Science

Volumn 30, Issue 3, 2004, Pages 255-266

  Blessing, Frithjof ^a   Wang, Ying ^a   Walli, Autar K ^a   Seidel, Dietrich ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coronary heart disease (CHD); H.E.L.P.; Peripheral vascular disease (PVD); Plasmat futura; Preeclampsia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CLOPIDOGREL; COLESTYRAMINE; COUMARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HEPARIN; HETASTARCH; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PENTOXIFYLLINE; PREDNISOLONE; SIMVASTATIN;

ADJUVANT THERAPY; APHERESIS; ATHEROSCLEROSIS; BLEEDING; BLOOD RHEOLOGY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; FAMILIAL HYPERCHOLESTEROLEMIA; GRAFT OCCLUSION; HEARING LOSS; HEART TRANSPLANTATION; HEPARIN MEDIATED EXTRACORPOREAL LOW DENSITY LIPOPROTEIN PRECIPITATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPOTENSION; ILEUM BYPASS; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIVER TRANSPLANTATION; MICROANGIOPATHY; NEPHROTIC SYNDROME; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PLASMAPHERESIS; PORTOCAVAL SHUNT; PREECLAMPSIA; STROKE;

ADULT; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; CHILD; COMPLEMENTARY THERAPIES; EXTRACORPOREAL CIRCULATION; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; TREATMENT OUTCOME;

EID: 2542539769     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2004.01.009     Document Type: Conference Paper

References (43)

1. DeGennes J.L., Touraine R., Maunand B., Truffert J., Laudat Ph. Formes homozygotes cutanéo-tendineuses de xanthomatose hypercholé sterolémique dans une observation familiale exemplaire. Essai de plasmaphérèse titre de traitement héroique. Soc. Méd. Hôspiteaux Paris. 118:1976;1377-1402
2. Lupien P.J., Moojani S., Award J. A new approach to the management of familial hypercholesterolemia: removal of plasma cholesterol based on the principle of affinity chromatography. Lancet. 1:1976;1261-1265
3. Thiery J., Walli A.K., Janning G., Seidel D. Low density lipoprotein plasmapheresis with and without Lovastatin in the treatment of the homozgous form of familial hypercholesterolaemia. Dur. J. Pediatric. 149:1990;716-721
4. Walzl M., Lechner H., Walzl B., Schied G. First experiences with the heparin-induced extracorporeal LDL-precipitation in the treatment for critical limb ischaemia. Haemostasis. 23:1993;237-243
5. Suckfüll M. for the Hearing Loss Study Group. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet. 360:2002;1811-1817
6. Seidel D., Wieland H. Ein neues verfahren zur selektiven messung und extrakorporalen elimination von low-density lipoproteinen. J. Clin. Chem. Clin. Biochem. 20:1982;684-685
7. Armstrong VW. Die säureinduzierte Präzipitation von Low-Density Lipoproteinen mit Heparin, Grundlagen zum H.E.L.P.-Verfahren. Habilitationsschrift, University of Göttingen, 1987
8. Seidel D. The H.E.L.P-system in the treatment of severe hypercholesterolaemia acute and long-term experience. Malmendier C.L., et al. Hypercholesterolemia hypocholesterolemia hypertriglyceridemia. 1990;155-159 Plenum Press, New York
9. Eisenhauer T., Armstrong V.W., Wieland H., Fuchs C., Scheler F., Seidel D. Selective removal of low-density lipoproteins (LDL) by precipitation at low pH: first clinical application of the H.E.L.P. system. Klin. Wochenschr. 65:1987;161-168
10. Würzner R., Schuff-Werner P., Franzke A., Nitze R., Oppermann M., Armstrong V.W., et al. Complement activation and depletion during LDL-apheresis by heparin-induced extracorporeal LDL-precipitation (H.E.L.P.). Eur. J. Clin. Invest. 21:1991;288-294
11. Wieland E., Schettler V., Armstrong V.W. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis. 162:2002;187-191
12. Thiery J., Seidel D. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia. Transfus. Sci. 14:1993;249-259
13. Seidel D. Apheresis. In: Kostner GM, Kostner KM, Kostner B, editors. Atherosclerosis: risk factors, diagnosis, and treatment. Monduzzi Editore S.p.A.-MEDIMOND Inc., 2002. p. 609-14
14. Scandinavian Simvastatin Survial Studa Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survial Study (4S). Lancet. 344:1994;1383-1389
15. Goldstein J.L., Brown M.S. Familial hypercholesterolemia. Stanbury J.B., Wyngaarden J.B., Fredrickson D.S., Goldstein J.L., Brown M.S. The metabolic basis of inherited disease. 1983;672-712 McGraw Hill Book Co, New York
16. Thiery J., Armstrong V.W., Eisenhauer T., Adam R., Janning G., Creutzfeldt W., et al. Combination of simvastatin and heparin-induced extracorporeal LDL/fibrinogen-precipitation (H.E.L.P.) in the treatment of hypercholesterolemia in CAD-patients. Crepaldi G., et al. Atherosclerosis VIII. 1989;831-835 Elsevier Science Publishers B.V. (Biomedical Division)
17. Reichart B., Meiser B.M., Wenke K., Brandl U., Seidel D., Thiery J. What is the role of lipid lowering therapy in heart-allograft failure? Kidney Int. Suppl. 52:1995;52-55
18. Jaeger B.R., Meiser B., Nagel D., Überfuhr P., Thiery J., Brandl U., et al. Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation. 96:1997;154-158
19. Park J.W., Merz M., Braun P. Regression of transplant coronary artery disease during chronic low-density lipoprotein apheresis. J. Heart Lung Transplant. 16:1997;290-297
20. Thiery J., Ivandic B., Bahlmann G., Walli A.K., Seidel D. Hyperlipoprotein (a)aemia in nephrotic syndrome. Eur. J. Clin. Invest. 26:1996;316-321
21. Wilson W., Byl F., Laird N. The efficiency of steroids in the treatment of idiopathic sudden hearing loss: a double blind clinical study. Arch. Otolaryngol. 106:1980;772-776
22. Moskowitz D., Lee K., Smith H.W. Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope. 94:1984;663-666
23. Suzuki K., Kaneko M., Murai K. Influence of serum lipids on auditory function. Laryngoscope. 110:2000;1736-1738
24. Futterman L.G., Lemberg L. Peripheral arterial disease is only the tip of the atherosclerotic "iceberg" Am. J. Crit. Care. 11:2002;390-394
25. Ulutin O.N. Atherosclerosis and hemostasis. Semin. Thromb. Hemost. 12:1986;156-174
26. Ridker P.M., Stampfer M.J., Rifai N. Novel risk factors for systemic atherosclerosis. JAMA. 285:2001;2481-2485
27. Sato Motoyoshi, Amano Izumi Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis. Ther. Apher. Dial. 7:2003;419-424
28. Asahi Takashi, Yamamoto Takashi, Kutsuki Hidetoshi Blood purification therapies using dextran sulphate cellulose columns liposorber and selesorb. Ther. Apher. Dial. 7:2003;73-77
29. Kamimura Motohiro, Matsuo Masaki, Miyahara Takashi, et al. Improvements in artery occlusion by low-density lipoprotein apheresis in a patient with peripheral arterial disease. Ther. Apher. 6:2002;467-470
30. Fowkes F.G.R. Fibrinogen and peripheral arterial disease. Eur. Heart J. 16:1995;36-41
31. Tkáč I., Molčányiová A. Fibrinogen and albuminuria are related to the presence and severity of peripheral arterial disease in women with type 2 diabetes mellitus. J. Vasc. Dis. 48:1997;715-719
32. McDermott M.M., Greenland P., Green D., Guralnik J.M., et al. D-Dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation. 107:2003;3191-3198
33. Erren M., Reinecke H., Junker R., Fobker M., et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscl. Thromb. Vasc. Biol. 19:1999;2355-2363
34. Blann A.D., Seigneur M., Steiner M., Miller J.P., McCollum C.N. Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking, and in the prediction of adverse events. Thromb. Haemost. 79:1998;1080-1085
35. Morishita R., Sakaki M., Yamamoto K., Aoki M., et al. Impairment of collateral formation in lipoprotein (a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation. 105:2002;1491-1496
36. Agishi T., Naganuma S., Miura A., Ohashi N., Ota K., Nomura M., et al. Treatment of malcirculation in lower extremities by LDL (low density lipoprotein) adsorption. J. Jpn. Soc. Dial. Ther. 23:1990;1295-1300
37. Fuda Y. Efficacy of LDL apheresis on the treatment of patients with arteriosclerotic obliterans without LDL hypercholesterolemia. Jpn. J. Artif. Organs. 23:1994;118
38. Onoyama O. Case report on LDL apheresis treatment for a patient with peripheral arterial occlusive disease without hypercholesterolemia. J. Jpn. Soc. Dial. Ther. 29:1996;850
39. Lechner H., Walzl M., Walzl-Lechner B., Kleinert G., Köck T. The impact of H.E.L.P. on haemorheology in peripheral arterial disease. Clin. Hemorheol. 14:1994;181-188
40. August P. Preeclampsia: new thoughts on an ancient problem (Greenwich). J. Clin. Hypertens. 2:2000;115-123
41. Pfefferkorn T.K., Knüppel H.P., Jaeger B.R., Thiery J., Hamann G.F. Increased cerebral CO2 reactivity after heparin-mediated extracorporeal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia. Stroke. 30:1999;1802-1806
42. Walzl M., Schied G., Walzl B. Effects of ameliorated haemorheology on clinical symptoms in cerebrovascular disease. Atherosclerosis. 139:1998;385-389
43. Armstrong V.W., Schleef J., Thiery J., Muche R., Schuff-Werner P., Eisenhauer T., et al. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein (a): kinetic analysis of the post-treatment return to baseline levels. Eur. J. Clin. Invest. 19:1989;235-240